Innovation Endeavors’ Joel Dudley on growing interest in life sciences with new fund — and why he hates ‘techbio’
26 Jan 2024
Acquisition
Co-founded by former Google CEO Eric Schmidt, tech venture capital firm Innovation Endeavors announced a new $630 million fund Thursday — but “expect life sciences and healthcare to represent a major portion of the fund,” partner Joel Dudley told Endpoints News.
An investor in Uber and SoFi, Innovation Endeavors has been increasingly involved in the biotech space over the past few years. It has put money into companies like Eikon Therapeutics and Zymergen — which was bought by Ginkgo Bioworks in 2022 following a major implosion — and more recently, Think Bioscience and BioLoomics.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.